MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

MDT

86.5

+0.42%↑

115.44

+0.79%↑

VEEV

173.86

+0.6%↑

HQY

84.6

+1.48%↑

PHR.US

8.34

-0.6%↓

Strona główna・Stock List・AnaptysBio Inc

AnaptysBio Inc

Closed

SectorHealthcare

57.89 1.9

Buy Sell

Overview

Share price change

24h

Current

Min

57.4

Max

59.74

Key metrics
By Trading Economics
Income	35M 50M
Sales	32M 108M
Profit margin	45.833
Employees	104
EBITDA	29M 68M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+49.83% upside

Dividends
By Dow Jones
Next Earnings	1 maj 2026

Market Stats
By TradingEconomics
Market Cap	56M 1.6B
Previous open	55.99
Previous close	57.89

News Sentiment

By Acuity

38%

62%

135 / 349 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

19.25 / 21.135 Support & Resistance

AnaptysBio Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

2 kwi 2026, 17:11 UTC

Major Market Movers

Major News Events

Home Depot Shares Hit 52-Week Low as Iran War Threatens Housing Rebound

2 kwi 2026, 17:10 UTC

Major News Events

ECB's Next Move Likely a Rate Rise, But Timing Unclear Amid Iran War, Villeroy Says

3 kwi 2026, 00:00 UTC

Major News Events

How Insulated Is the U.S. Economy From the Iran War? -- WSJ

2 kwi 2026, 23:47 UTC

Market Talk

Major News Events

Nikkei Might Rise After Thursday's Selloffs -- Market Talk

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Under the Terms of the Agreement, Funds Managed by Boyu Cap Now Hold a 60% Stake in Starbucks China Retail Ops >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Retains 40% Ownership Interest and Continues to Own and License the Brand and Intellectual Property to JV >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks: Joint Venture Is Designed to Enhance Starbucks Ability to Expand Footprint, Deepen Local Relevance >SBUX

2 kwi 2026, 21:05 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Cap: Finalize Joint Venture to Accelerate Long-Term Growth in China

2 kwi 2026, 21:01 UTC

Major News Events

Investors Waver after Trump Speech on Iran, Ending Two-Day Surge in Stocks -- WSJ

2 kwi 2026, 20:59 UTC

Acquisitions, Mergers, Takeovers

Starbucks and Boyu Capital Finalize China JV

2 kwi 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2 kwi 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

2 kwi 2026, 20:41 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 20:32 UTC

Market Talk

Higher Gas Prices Intensify K-Shaped Economy -- Market Talk

2 kwi 2026, 20:30 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 20:09 UTC

Market Talk

Eli Lilly On More Equal Footing With Rival With Weight-Loss Pill -- Market Talk

2 kwi 2026, 20:01 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:46 UTC

Market Talk

Is Oil the New GameStop? -- Market Talk

2 kwi 2026, 19:35 UTC

Market Talk

U.S. Natural Gas Falls As Storage Injection Season Gets Under Way -- Market Talk

2 kwi 2026, 19:29 UTC

Acquisitions, Mergers, Takeovers

SBA Communications Stock Jumps on Report of Sale Talks -- Barrons.com

2 kwi 2026, 19:24 UTC

Market Talk

Major News Events

Oil Futures Jump Ahead of Long Weekend -- Market Talk

2 kwi 2026, 19:20 UTC

Market Talk

Nike Has Yet to Show That a Turnaround is on Horizon -- Market Talk

2 kwi 2026, 19:01 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: ATDA Agreement to Guarantee Jobs for Life for Union Employees After Norfolk Southern Deal

2 kwi 2026, 19:00 UTC

Acquisitions, Mergers, Takeovers

Union Pacific: Agreement Reached With American Train Dispatchers Association

2 kwi 2026, 18:24 UTC

Acquisitions, Mergers, Takeovers

Globalstar Stock Rises on Amazon Deal Report. Why Apple Could Scuttle the Launch. -- Barrons.com

2 kwi 2026, 17:44 UTC

Market Talk

Major News Events

Oil Supply Squeeze Puts Refiners in a Quandary -- Market Talk

2 kwi 2026, 17:32 UTC

Major News Events

Amazon to Boost Fuel Surcharges on Third-Party Sellers as Costs Rise -- Barrons.com

2 kwi 2026, 17:26 UTC

Earnings

These Stocks Are Today's Movers: Tesla, Globalstar, Blue Owl, United Airlines, Carnival, Lumentum, and More -- Barrons.com

2 kwi 2026, 17:17 UTC

Market Talk

Shares of Canadian Exports Heading to U.S. Continues to Slide -- Market Talk

2 kwi 2026, 17:09 UTC

Market Talk

Major News Events

Oil Holds Gains After Trump Speech Disappointed Market -- Market Talk

Peer Comparison

Price change

AnaptysBio Inc Forecast

Price Target

By TipRanks

49.83% upside

12 Months Forecast

Average 85 USD 49.83%

High 140 USD

Low 50 USD

Based on 10 Wall Street analysts offering 12 month price targets forAnaptysBio Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to AnaptysBio Inc - Dist in the past 3 months.

Technical Score

By Trading Central

19.25 / 21.135Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Sentiment

By Acuity

135 / 349 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.